BofA Securities on Sarepta Therapeutics (SRPT): sNDAs 'positive first step' but regulatory risk continues
Tweet Send to a Friend
BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $19.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
